^
Association details:
Biomarker:No biomarker
Cancer:Colorectal Cancer
Drug:Alymsys (bevacizumab-maly) (VEGF-A inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A1 - Approval
Source:
Published date:
04/13/2022
Excerpt:
Alymsys is a vascular endothelial growth factor inhibitor indicated for the treatment of...Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment...Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidineoxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen.
Secondary therapy:
5-fluorouracil; irinotecan; oxaliplatin